Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Identifying HER2+ breast cancer subgroups associated with prognosis in the ALTTO trial

Mattia Rediti • 12 Sep 2022
ESMO 2022
Breast Cancer Antibodies Trastuzumab

Mattia Rediti, MD, Institut Jules Bordet, Anderlecht, Belgium, discusses the identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the Phase III ALTTO (NCT00490139) trial. A supervised top-down approach identified 4 biologically-driven clusters in HER2-positive breast cancer which can be integrated with PAM50. Overall, these findings support the evaluation of de-escalation approaches in luminal and immune-enriched subgroups. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

More from Mattia Rediti

The evolution of HER2-low-positive breast cancer as a clinical subtype
1:10
The evolution of HER2-low-positive breast cancer as a clinical subtype
Mattia Rediti • 12 Sep 2022
Moving ADCs to first-line therapy in metastatic HER2+ breast cancer
0:54
Moving ADCs to first-line therapy in metastatic HER2+ breast cancer
Mattia Rediti • 12 Sep 2022

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals